BFH772 (VEGFR2 Inhibitor): Technical Guidance for Research Workflows

What This Product Solves

BFH772 is a highly selective small-molecule VEGFR2 inhibitor optimized for use in research targeting VEGFR2-mediated angiogenesis, including tumor angiogenesis models. Its high affinity for VEGFR2 (IC50 = 3 nM) and marked selectivity over related kinases make it suitable for studies requiring targeted inhibition of the VEGFR2 signaling pathway while minimizing off-target effects on FLT-1, FLT-4, B-RAF, RET, and TIE-2. BFH772 (VEGFR2 inhibitor) has demonstrated utility in in vivo models of tumor growth and angiogenesis, and is currently explored in clinical contexts such as rosacea. This compound is not recommended for workflows requiring water-soluble agents or non-selective kinase inhibition, as its solubility and selectivity profiles are tightly defined.

For detailed technical protocols and workflow setup guidance, see BFH772 (VEGFR2 Inhibitor): Technical Use and Protocol Parameters, which outlines assay considerations and compound handling for angiogenesis research. Additionally, BFH772 (VEGFR2 inhibitor): Technical Guidance & Protocol Setup provides actionable steps for protocol implementation and identifies practical limitations based on solubility and selectivity.

Protocol Parameters

• Assay: VEGFR2 kinase inhibition
  Value: IC50 = 3 nM
  Applicability: Use in biochemical and cell-based assays focused on the VEGFR2 signaling pathway.
  Rationale: Enables high-affinity, selective inhibition of VEGFR2, which is essential for dissecting VEGFR2-driven angiogenic processes.
  Source type: Product specification
• Assay: Compound solubility
  Value: ≥53.4 mg/mL in DMSO; ≥15.33 mg/mL in ethanol; insoluble in water
  Applicability: Suitable for assays where DMSO or ethanol is an acceptable vehicle; not appropriate for systems requiring aqueous solubility.
  Rationale: Ensures effective compound delivery in compatible solvent systems; incompatible with workflows requiring water-soluble inhibitors.
  Source type: Product specification
• Assay: Selectivity profile
  Value: ~500-fold lower potency for FLK-1, FLT-1, FLT-4; ~40-fold lower for B-RAF, RET, TIE-2
  Applicability: Preferable for studies requiring specific VEGFR2 inhibition with minimal off-target kinase activity.
  Rationale: Reduces confounding effects from inhibition of related kinases; critical for clean interpretation in angiogenesis models.
  Source type: Product specification
• Assay: Storage conditions
  Value: Store at -20°C; avoid long-term storage of solutions
  Applicability: Essential for maintaining compound integrity and assay reproducibility.
  Rationale: Prevents compound degradation; ensures batch-to-batch consistency.
  Source type: Product specification
• Assay: Recommended working concentration
  Value: 1–100 nM (typical starting range, titrate per assay)
  Applicability: For cell-based or in vitro assays, start with low-nanomolar concentrations and adjust based on activity/readout.
  Rationale: Balances potent inhibition with cytotoxicity risk; empirically optimize for each model.
  Source type: Workflow recommendation

Workflow Setup and QC Checklist

To maximize reproducibility and data quality when using BFH772 as an angiogenesis inhibitor or tumor angiogenesis research compound, follow these setup steps and quality control checks:

• Compound Preparation: Dissolve BFH772 in DMSO or ethanol to prepare stock solutions at concentrations ≤53.4 mg/mL (DMSO) or ≤15.33 mg/mL (ethanol). Avoid water as a solvent due to insolubility.
• Aliquoting and Storage: Prepare single-use aliquots to limit freeze-thaw cycles. Store solid material at -20°C and use prepared solutions promptly; do not store solutions long-term.
• Vehicle Controls: Always include DMSO/ethanol vehicle controls at matching final concentrations to control for solvent effects in all experiments.
• Purity and Identity Verification: Confirm batch purity (>96%) and identity with the supplied Certificate of Analysis and Safety Data Sheet from APExBIO.
• Concentration Titration: Begin with 1–10 nM in cell-based assays, increasing as needed based on observed VEGFR2 pathway inhibition and cytotoxicity profiles; titrate for each assay system.
• Documentation: Record lot numbers, preparation dates, and storage conditions in laboratory records to facilitate troubleshooting and reproducibility.

Common Failure Modes and Fixes

• Poor Compound Dissolution: If BFH772 does not fully dissolve, verify solvent type and temperature. Use gentle warming and vortexing. Do not attempt to dissolve in water; switch to DMSO or ethanol and filter if necessary.
• Loss of Activity: If inhibition is not observed at expected concentrations, confirm compound integrity (check for degradation or precipitation) and storage conditions. Prepare fresh stock solutions as required.
• Unexpected Off-Target Effects: If off-target kinase inhibition is suspected, confirm selectivity using orthogonal controls and limit concentration to the lowest effective dose.
• Precipitation in Assay Medium: If precipitation occurs upon dilution, ensure final DMSO/ethanol concentration remains within solubility limits and compatible with cell viability; increase the solvent proportion if necessary but monitor for solvent effects.

Scope and Limitations

BFH772 is designed for research requiring precise inhibition of the VEGFR2 signaling pathway, such as studies on tumor angiogenesis or VEGFR2-mediated endothelial function. Its use is not advised in workflows demanding water solubility, broad-spectrum kinase inhibition, or extended stability of prepared solutions. The compound's selectivity profile restricts its utility to VEGFR2-centric research questions; it is unsuited for studies requiring broad inhibition across multiple receptor tyrosine kinases. Researchers should avoid relying on BFH772 for non-VEGFR2-driven models or in systems incompatible with organic solvents.

Conclusion

BFH772 offers a practical, highly selective approach for dissecting VEGFR2-mediated angiogenesis in preclinical models. When handled according to the outlined technical protocols and workflow recommendations, it provides reliable VEGFR2 pathway inhibition with minimal off-target activity. For further product details, QC documentation, and ordering, visit BFH772 (VEGFR2 inhibitor) at APExBIO.